Literature DB >> 10506904

Treatment of acute opioid withdrawal with ibogaine.

K R Alper1, H S Lotsof, G M Frenken, D J Luciano, J Bastiaans.   

Abstract

Ibogaine is an alkaloid with putative effect in acute opioid withdrawal. Thirty-three cases of treatments for the indication of opioid detoxification performed in non-medical settings under open label conditions are summarized involving an average daily use of heroin of .64 +/- .50 grams, primarily by the intravenous route. Resolution of the signs of opioid withdrawal without further drug seeking behavior was observed within 24 hours in 25 patients and was sustained throughout the 72-hour period of posttreatment observation. Other outcomes included drug seeking behavior without withdrawal signs (4 patients), drug abstinence with attenuated withdrawal signs (2 patients), drug seeking behavior with continued withdrawal signs (1 patient), and one fatality possibly involving surreptitious heroin use. The reported effectiveness of ibogaine in this series suggests the need for systematic investigation in a conventional clinical research setting.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10506904     DOI: 10.1080/105504999305848

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  24 in total

1.  In vitro activities of iboga alkaloid congeners coronaridine and 18-methoxycoronaridine against Leishmania amazonensis.

Authors:  Jan Carlo Delorenzi; Leonardo Freire-de-Lima; Cerli R Gattass; Deise de Andrade Costa; Liwen He; Martin E Kuehne; Elvira M B Saraiva
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

Review 2.  Herbal medicines for the management of opioid addiction: safe and effective alternatives to conventional pharmacotherapy?

Authors:  Jeanine Ward; Christopher Rosenbaum; Christina Hernon; Christopher R McCurdy; Edward W Boyer
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

Review 3.  Kappa opioids as potential treatments for stimulant dependence.

Authors:  Thomas E Prisinzano; Kevin Tidgewell; Wayne W Harding
Journal:  AAPS J       Date:  2005-10-19       Impact factor: 4.009

4.  A meta-analysis of Chinese herbal medicine in treatment of managed withdrawal from heroin.

Authors:  Ting-ting Liu; Jie Shi; David H Epstein; Yan-Ping Bao; Lin Lu
Journal:  Cell Mol Neurobiol       Date:  2008-06-27       Impact factor: 5.046

5.  Plants with Anti-Addictive Potential.

Authors:  Eduardo Luis Konrath; Marcelo Dutra Arbo; Bruno Dutra Arbo; Mariana Appel Hort; Elaine Elisabetsky; Mirna Bainy Leal
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  A Mixed-Method Analysis of Persisting Effects Associated with Positive Outcomes Following Ibogaine Detoxification.

Authors:  Alan K Davis; Elise Renn; Austin-Marley Windham-Herman; Martin Polanco; Joseph P Barsuglia
Journal:  J Psychoactive Drugs       Date:  2018-07-18

7.  An Ethical Exploration of Barriers to Research on Controlled Drugs.

Authors:  Michael H Andreae; Evelyn Rhodes; Tyler Bourgoise; George M Carter; Robert S White; Debbie Indyk; Henry Sacks; Rosamond Rhodes
Journal:  Am J Bioeth       Date:  2016       Impact factor: 11.229

Review 8.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

9.  Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption.

Authors:  Dao-Yao He; Nancy N H McGough; Ajay Ravindranathan; Jerome Jeanblanc; Marian L Logrip; Khanhky Phamluong; Patricia H Janak; Dorit Ron
Journal:  J Neurosci       Date:  2005-01-19       Impact factor: 6.167

Review 10.  Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence.

Authors:  Kelly E Dunn; Andrew S Huhn; Cecilia L Bergeria; Cassandra D Gipson; Elise M Weerts
Journal:  J Pharmacol Exp Ther       Date:  2019-08-07       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.